Literature DB >> 11585779

Antifungal susceptibility testing: practical aspects and current challenges.

J H Rex1, M A Pfaller, T J Walsh, V Chaturvedi, A Espinel-Ingroff, M A Ghannoum, L L Gosey, F C Odds, M G Rinaldi, D J Sheehan, D W Warnock.   

Abstract

Development of standardized antifungal susceptibility testing methods has been the focus of intensive research for the last 15 years. Reference methods for yeasts (NCCLS M27-A) and molds (M38-P) are now available. The development of these methods provides researchers not only with standardized methods for testing but also with an understanding of the variables that affect interlaboratory reproducibility. With this knowledge, we have now moved into the phase of (i) demonstrating the clinical value (or lack thereof) of standardized methods, (ii) developing modifications to these reference methods that address specific problems, and (iii) developing reliable commercial test kits. Clinically relevant testing is now available for selected fungi and drugs: Candida spp. against fluconazole, itraconazole, flucytosine, and (perhaps) amphotericin B; Cryptococcus neoformans against (perhaps) fluconazole and amphotericin B; and Aspergillus spp. against (perhaps) itraconazole. Expanding the range of useful testing procedures is the current focus of research in this area.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11585779      PMCID: PMC88997          DOI: 10.1128/CMR.14.4.643-658.2001

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  205 in total

Review 1.  In vitro antifungal susceptibility methods and clinical implications of antifungal resistance.

Authors:  A Espinel-Ingroff; D W Warnock; J A Vazquez; B A Arthington-Skaggs
Journal:  Med Mycol       Date:  2000       Impact factor: 4.076

2.  Correlation between in vitro susceptibility determined by E test and response to therapy with amphotericin B: results from a multicenter prospective study of candidemia.

Authors:  C J Clancy; M H Nguyen
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

3.  In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods.

Authors:  R E Lewis; M E Klepser; M A Pfaller
Journal:  Diagn Microbiol Infect Dis       Date:  2000-02       Impact factor: 2.803

4.  Multisite reproducibility of the Etest MIC method for antifungal susceptibility testing of yeast isolates.

Authors:  M A Pfaller; S A Messer; A Bolmström; F C Odds; J H Rex
Journal:  J Clin Microbiol       Date:  1996-07       Impact factor: 5.948

5.  Quality control limits for broth microdilution susceptibility tests of ten antifungal agents.

Authors:  A L Barry; M A Pfaller; S D Brown; A Espinel-Ingroff; M A Ghannoum; C Knapp; R P Rennie; J H Rex; M G Rinaldi
Journal:  J Clin Microbiol       Date:  2000-09       Impact factor: 5.948

6.  The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance.

Authors:  M H Nguyen; J E Peacock; A J Morris; D C Tanner; M L Nguyen; D R Snydman; M M Wagener; M G Rinaldi; V L Yu
Journal:  Am J Med       Date:  1996-06       Impact factor: 4.965

7.  Clinical response to ketoconazole of HIV-related oral candidosis is predicted by Odds' relative growth method of susceptibility testing.

Authors:  J D Cartledge; J Midgley; B G Gazzard
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

Review 8.  Antifungal drug resistance in pathogenic fungi.

Authors:  H Vanden Bossche; F Dromer; I Improvisi; M Lozano-Chiu; J H Rex; D Sanglard
Journal:  Med Mycol       Date:  1998       Impact factor: 4.076

9.  Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans.

Authors:  A Espinel-Ingroff; J L Rodríguez-Tudela; J V Martínez-Suárez
Journal:  J Clin Microbiol       Date:  1995-12       Impact factor: 5.948

10.  Pharmacokinetics of fluconazole in immune-compromised children with leukemia or other hematologic diseases.

Authors:  R E Seay; T A Larson; J P Toscano; B C Bostrom; M C O'Leary; D L Uden
Journal:  Pharmacotherapy       Date:  1995 Jan-Feb       Impact factor: 4.705

View more
  108 in total

1.  Clinical evaluation of a frozen commercially prepared microdilution panel for antifungal susceptibility testing of seven antifungal agents, including the new triazoles posaconazole, ravuconazole, and voriconazole.

Authors:  M A Pfaller; D J Diekema; S A Messer; L Boyken; H Huynh; R J Hollis
Journal:  J Clin Microbiol       Date:  2002-05       Impact factor: 5.948

2.  Correlation between E-test, disk diffusion, and microdilution methods for antifungal susceptibility testing of fluconazole and voriconazole.

Authors:  Madonna J Matar; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

3.  Comparative evaluation of NCCLS M27-A and EUCAST broth microdilution procedures for antifungal susceptibility testing of candida species.

Authors:  Manuel Cuenca-Estrella; Wendy Lee-Yang; Meral A Ciblak; Beth A Arthington-Skaggs; Emilia Mellado; David W Warnock; Juan L Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2002-11       Impact factor: 5.191

4.  Interlaboratory evaluation of hematocytometer method of inoculum preparation for testing antifungal susceptibilities of filamentous fungi.

Authors:  J L Rodriguez-Tudela; Erja Chryssanthou; Evangelia Petrikkou; Juan Mosquera; David W Denning; Manuel Cuenca-Estrella
Journal:  J Clin Microbiol       Date:  2003-11       Impact factor: 5.948

5.  Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.

Authors:  Rama Ramani; Madhurama Gangwar; Vishnu Chaturvedi
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

6.  Caspofungin activity against clinical isolates of fluconazole-resistant Candida.

Authors:  Michael A Pfaller; Shawn A Messer; Linda Boyken; Cassie Rice; Shailesh Tendolkar; Richard J Hollis; Daniel J Diekema
Journal:  J Clin Microbiol       Date:  2003-12       Impact factor: 5.948

7.  Collaborative study of the NCCLS and flow cytometry methods for antifungal susceptibility testing of Candida albicans.

Authors:  Vishnu Chaturvedi; Rama Ramani; Michael A Pfaller
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

8.  Collaborative study of antibiotic medium 3 and flow cytometry for identification of amphotericin B-resistant Candida isolates.

Authors:  Vishnu Chaturvedi; Rama Ramani; John H Rex
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

9.  Effect of pH on the in vitro activities of amphotericin B, itraconazole, and flucytosine against Aspergillus isolates.

Authors:  D T A Te Dorsthorst; J W Mouton; C J P van den Beukel; H A L van der Lee; J F G M Meis; P E Verweij
Journal:  Antimicrob Agents Chemother       Date:  2004-08       Impact factor: 5.191

10.  In vitro activities of retigeric acid B alone and in combination with azole antifungal agents against Candida albicans.

Authors:  Lingmei Sun; Shujuan Sun; Aixia Cheng; Xiuzhen Wu; Yu Zhang; Hongxiang Lou
Journal:  Antimicrob Agents Chemother       Date:  2009-01-26       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.